When was 89bio founded?

89bio was founded in 2018 and raised its 1st funding round within a year of its incorporation.

Where is 89bio located?

89bio is headquartered in San Francisco, United States. It is registered at 142 Sansome St 2nd Floor, San Francisco, CA 94104.

How many employees does 89bio have?

As of Sep 30, 2026, the latest employee count at 89bio is 110.

Is 89bio a funded company?

89bio is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Oct 25, 2018.

How much is 89bio worth?

The last known valuation of 89bio was $***** as of Sep 17, 2025.

When was the latest funding round of 89bio?

89bio's latest funding was a $***** Series A round on Oct 25, 2018, with participation from 4 investors.

Where does 89bio rank among its competitors?

89bio ranks 5th amongst 45 active competitors, of which 11 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Sernova, which secured $345K in Oct, 2025.

Who are the top competitors of 89bio?

89bio's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept. Among them, Sernova secured the most recent funding round in October, 2025.

89bio - 2026 Company Profile, Team, Funding, Competitors & Financials

Q: Is 89bio an acquired company?

89bio got acquired by Roche on Sep 17, 2025.

89bio is an acquired company based in San Francisco (United States), founded in 2018. It operates as a Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders. 89bio has raised $60M in funding from Orbimed and Longitude Capital, with last known valuation of $*****. The company has 45 active competitors, including 11 funded and 19 that have exited. Its top competitors include companies like Rhythm Pharmaceuticals, MannKind Corp and Corcept.

Company Details

89bio is developing therapies for treating nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. The lead candidate is BIO89-100, which is a long-acting glycopegylated fibroblast growth factor 21 analog used for treating NASH. They have developed the product from their proprietary glycopegylation technology. The candidate is in phase I clinical trial.

Website: 89bio.com
Email ID: *****@89bio.com
Registered Address: 142 Sansome St 2nd Floor, San Francisco, CA 94104

Key Metrics

Founded Year

2018

Location

San Francisco, United States

Stage

Acquired

Total Funding

$60M in 1 round

Latest Funding Round

Series A, Oct 25, 2018, $*****

Last Known Valuation

$***** as on Sep 17, 2025

Investors

Orbimed & 4 more

Ranked

5^th among 45 active competitors

Employee Count

110 as on Sep 30, 2026

Similar Companies

Rhythm Pharmaceuticals & 61 more

Exit Details

Acquired by Roche (Sep 17, 2025)

View 89bio's full profile

89bio is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
89bio, Inc. CIN: 1785173 , United States, Active	Jun 27, 2019	-	-	-
89BIO, INC CIN: 7491937 , United States, Active	Jul 01, 2018	-	70 (As on Dec 31, 2023)	-

89bio got acquired by Roche on Sep 17, 2025 at an acquisition amount of $*****.

Click here to take a look at 89bio's acquisition in detail

89bio has raised a total funding of $60M over 1 round. Its latest funding round was a Series A round on Oct 25, 2018 for $*****. 4 investors participated in its latest round. 89bio has 5 institutional investors.

Here is the list of recent funding rounds of 89bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 25, 2018	3995351	Series A	5097367	3578371	4680835	3514293

Access funding benchmarks and valuations. Sign up today!

View details of 89bio's funding rounds and investors

89bio's employee count trend

89bio has 110 employees as of Sep 26. Here is 89bio's employee count trend over the years:

Uncover 89bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of 89bio include Rhythm Pharmaceuticals, MannKind Corp and Corcept. Here is the list of Top 10 competitors of 89bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 9 others	70/100
2nd	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Ignite 500 & 1 others	70/100
3rd	Corcept 1998, Menlo Park (United States), Public	Developer of cortisol modulators for the treatment of various diseases	-	Longitude Capital, BioBrit & 7 others	68/100
4th	Genfit 1999, Loos (France), Public	Therapeutics for cardiometabolic and neurodegenerative diseases.	-	Eiffel Investment Group, Ridgeback Capital Management ... & 2 others	59/100
5th	89bio 2018, San Francisco (United States), Acquired	Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders	$60M	RA Capital Management, Longitude Capital & 3 others	59/100
6th	Sernova 1998, London (Canada), Public	Regenerative medicine to deliver proteins and hormones for disease treatment	-	National Research Council Canada, Evotec & 1 others	57/100
7th	Verdiva Bio 2024, London (United Kingdom), Series A	Developer of oral and injectable peptide therapies for metabolic diseases	$411M	General Atlantic, Forbion & 5 others	56/100
8th	OptiBiotix Health 2012, York (United Kingdom), Public	Developer of microbial strains for the treatment of human metabolic diseases	-	Seneca EIS Portfolio Fund, Mercia & 2 others	55/100
9th	ViaCyte 1999, San Diego (United States), Acquired	Developer of cell therapy for the treatment of diabetes	$389M	Bain Capital Life Sciences, Sanderling Ventures ... & 21 others	54/100
10th	PhaseBio Pharmaceuticals 2002, Malvern (United States), Public	Developer of novel drugs to treat metabolic and cardiopulmonary disorders	$152M	Rock Springs Capital, AstraZeneca & 12 others	54/100